cxcr4 blocking antibody  (MedChemExpress)

Journal: Bioactive Materials

Article Title: MSC-mimicking nanovesicle embedded bio-adhesive hydrogel for dual immunomodulation and osteogenesis to promote maxillofacial bone regeneration

doi: 10.1016/j.bioactmat.2026.02.032

Figure Lengend Snippet: nMSC@MT inheriting the original MSCs and could be effectively taken up by BMMSCs. a) Representative confocal images of PMVs with DiI-labeled cell membrane and Tht-labeled cytoplasm. Scale bar = 25 μm (above) and 1 μm (below). b) Illustration showing the co-extrusion procedure of nPMV and melatonin to obtain nMSC@MT. c) Representative TEM image of nMSC@MT. Scale bar = 100 nm. d, e) The sizes and the potential zetas of nPMV and nMSC@MT by DLS (n = 3). f, g) Coomassie brilliant blue and Western blot showing the preservation of stem cell markers, CD146, CD105, CD90, and functional protein, CXCR4, in PMV, nPMV, and nMSC@MT. h) DiI-labeled nMSC@MT (red) was detected in the cytoplasm of BMMSCs, suggesting the endocytosis of nMSC@MT. Scale bar = 10 μm. i) Immunofluorescence showing that a large amount of DiI-labeled nMSC@MT (red), released from the hydrogel, was taken up by CD146-labeled MSCs (green). Scale bar = 50 μm. j) BMMSCs uptake of DiI-labeled nMSC@MT in presence of blocking antibodies (anti-CXCR4) detected via flow cytometry. k) Analysis of the percentage of DiI positive cells in BMMSCs by flow cytometry (n = 3). l, m) Immunofluorescent staining images and corresponding semi-quantitative analysis (n = 3) of the uptake of DiI-labeled nPMV by BMMSCs in presence of blocking antibodies (anti-CXCR4). Scale bar = 50 μm. P-values are calculated using one-way ANOVA with Tukey's test, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, n.s. not significant ( b was created with bioRender. com).

Article Snippet: To evaluate the involvement of CXCR4 in the uptake of nPMV, prior to co-culture with BMMSCs, nPMV was pre-treated with 160 nM CXCR4 blocking antibody (Ulocuplumab, Cat. HY-P99272, MedChemExpress, China) at room temperature for 1 h. Then nPMV was introduced into BMMSC cultures and incubated for 24 h. Subsequent analyses included flow cytometric analysis and immunofluorescence staining. nPMV without blocking antibody was served as a control.

Techniques: Labeling, Membrane, Western Blot, Preserving, Functional Assay, Immunofluorescence, Blocking Assay, Flow Cytometry, Staining

Journal: JCI Insight

Article Title: iPSC-derived endothelial cell response to hypoxia via SDF1a/CXCR4 axis facilitates incorporation to revascularize ischemic retina

doi: 10.1172/jci.insight.131828

Figure Lengend Snippet: (A) Representative immunofluorescence images and (B) quantification of angiogenic invasion into collagen type I stromal cell–derived factor-1a (SDF1a) hydrogels (phalloidin in red, nuclei in blue; n = 9, n = 3). Tukey’s multiple comparisons test was conducted to determine statistical significance. (C) Representative flow cytometry histograms for CXCR4 in human-induced pluripotent stem cell–derived endothelial cells (hiPSC-ECs) and human retinal endothelial cells (HRECs) under atmospheric and hypoxic conditions. Percentages denote percent positive cells as compared to an IgG control. (D) Representative images of mouse OIR model retinas injected with hiPSC-ECs in PBS (left; n = 4) or hiPSC-ECs injected with C-X-C chemokine receptor type 4 (CXCR-4) blocking antibody (right; n = 7). Box represents 25th to 75th percentile, line at median value; whiskers represent minimum and maximum value. Significance level is set at ****P ≤ 0.0001. Scale bars: 100 μm (A); 200 μm (D).

Article Snippet: In a subset of C57BL/6J mice, hiPSC-ECs (50,000 cells/eye) were injected in the presence or absence of CXCR4 blocking antibody (R&D Systems).

Techniques: Immunofluorescence, Derivative Assay, Flow Cytometry, Injection, Blocking Assay

Journal: JCI Insight

Article Title: iPSC-derived endothelial cell response to hypoxia via SDF1a/CXCR4 axis facilitates incorporation to revascularize ischemic retina

doi: 10.1172/jci.insight.131828

Figure Lengend Snippet: hiPSC-ECs respond to hypoxic tissue environment in a mouse model of oxygen-induced retinopathy via stromal cell–derived factor-1a (SDF1a)/C-X-C chemokine receptor 4 (CXCR-4) axis, resulting in an integration with host vasculature compared with HRECs.

Article Snippet: In a subset of C57BL/6J mice, hiPSC-ECs (50,000 cells/eye) were injected in the presence or absence of CXCR4 blocking antibody (R&D Systems).

Techniques: Derivative Assay

Journal: International Journal of Molecular Sciences

Article Title: The CXCR4–CXCL12 -Axis Is of Prognostic Relevance in DLBCL and Its Antagonists Exert Pro-Apoptotic Effects In Vitro

doi: 10.3390/ijms20194740

Figure Lengend Snippet: CXCR4 and CXCL12 expression in DLBCL. ( a ) Expression analysis of CXCR4 and CXCL12 in non-neoplastic control germinal center B cells (GC-B) and diffuse large B cell lymphoma cells (DLBCL) consisting of DLBCL-NGCB and DLCBL-GCB, by RQ-PCR. GCB-DLBCL were further subdivided into primary (DLBCL-pGCB) and transformed DLBCL (DLBCL-pGCB) originating from follicular lymphoma. ( b ) Expression analysis of CXCR4 and CXCL12 in DLBCL samples with early (stage 1) and advanced stage (stage 2–4) (left graphs) and DLBCL samples with and without bone marrow infiltration (right graphs) by RQ-PCR. ( c ) Probability of 5-year-survival in DLBCL patients (our cohort left panel and the cohort of Lenz et al. right ) stratified by the third quartile of CXCR4 expression, respectively. ( d ) Representative immunohistochemical stains of CXCR4 (I–III) and CXCL12 (IV–VI) on DLBCL samples (magnification 20×). mRNA expression levels were calculated as a relative expression in comparison to the GC-B cells. All images were captured using an Olympus BX51 microscope and an Olympus E-330 camera.

Article Snippet: First, either the CXCR4 antagonists AMD3100, AMD070 or WK1 to a final concentration between 0.01–20 µM or blocking antibodies (10 µg/mL) targeting CXCR4 (clone: 9C4, MBL, Woburn, MA, USA), CXCR7 (clone: 11G8, ChemoCentryx Inc., Mountain View, CA, USA), or isotype controls were added to the cells and incubated for 45 min at 37 °C.

Techniques: Expressing, Transformation Assay, Immunohistochemical staining, Microscopy

Journal: International Journal of Molecular Sciences

Article Title: The CXCR4–CXCL12 -Axis Is of Prognostic Relevance in DLBCL and Its Antagonists Exert Pro-Apoptotic Effects In Vitro

doi: 10.3390/ijms20194740

Figure Lengend Snippet: Single nucleotide polymorphism occurring in the CDS of CXCR4 in our DLBCL cohort and investigated lymphoma cell lines.

Article Snippet: First, either the CXCR4 antagonists AMD3100, AMD070 or WK1 to a final concentration between 0.01–20 µM or blocking antibodies (10 µg/mL) targeting CXCR4 (clone: 9C4, MBL, Woburn, MA, USA), CXCR7 (clone: 11G8, ChemoCentryx Inc., Mountain View, CA, USA), or isotype controls were added to the cells and incubated for 45 min at 37 °C.

Techniques: Transformation Assay

Journal: International Journal of Molecular Sciences

Article Title: The CXCR4–CXCL12 -Axis Is of Prognostic Relevance in DLBCL and Its Antagonists Exert Pro-Apoptotic Effects In Vitro

doi: 10.3390/ijms20194740

Figure Lengend Snippet: CXCR4 and CXCL12 expression and BM infiltration. ( a ) Expression analysis of CXCR4 and CXCL12 in uninfiltrated and infiltrated bone marrow specimens at the time of diagnosis by RQ-PCR. ( b ) Expression analysis of CXCR4 and CXCL12 in infiltrated bone marrow biopsies and the respective paired sample in patients under remission by RQ-PCR. ( c ) Representative immunohistochemical stains of CXCR4 (I–II) and CXCL12 (III–IV) on selected bone marrow specimens of DLBCL patients (magnification 20×). (I) and (III) represent the CXCR4 and CXCL12 staining of uninfiltrated bone marrow specimens, and (II) and (IV) represent those of the infiltrated bone marrow specimens. mRNA expression levels were calculated as a relative expression in comparison to uninfiltrated bone marrow specimens. Each bar represents the mean values of expression levels ± standard error of the mean (SEM). The comparison of the expression levels was performed by using the Mann–Whitney U-test or the Student’s t-test. All images were captured using an Olympus BX51 microscope and an Olympus E-330 camera.

Article Snippet: First, either the CXCR4 antagonists AMD3100, AMD070 or WK1 to a final concentration between 0.01–20 µM or blocking antibodies (10 µg/mL) targeting CXCR4 (clone: 9C4, MBL, Woburn, MA, USA), CXCR7 (clone: 11G8, ChemoCentryx Inc., Mountain View, CA, USA), or isotype controls were added to the cells and incubated for 45 min at 37 °C.

Techniques: Expressing, Immunohistochemical staining, Staining, MANN-WHITNEY, Microscopy

Journal: International Journal of Molecular Sciences

Article Title: The CXCR4–CXCL12 -Axis Is of Prognostic Relevance in DLBCL and Its Antagonists Exert Pro-Apoptotic Effects In Vitro

doi: 10.3390/ijms20194740

Figure Lengend Snippet: Growth inhibition and apoptosis of B cell lymphoma cell lines upon treatment with CXCR4 antagonists. ( a ) Structure of the CXCR4 antagonists AMD3100, AMD070, and WK1. ( b ) Cell growth of SuDHL4 (as GCB-DLBCL model), RI-1 and U2932 (as NGCB-DLBCL model), and BL2 (as Burkitt model) cell lines in the presence of increasing concentrations (range: 1–90 µM) of the CXCR4 antagonists AMD3100, AMD070, its niacin derivative WK1 and niacin, respectively, as determined by the EZ4U proliferation assay and expressed by percentage of normal absorption. ( c ) Annexin V positivity of BL2 (as Burkitt model) and SuDHL4 (as GCB-DLBCL model) cells treated with AMD3100, AMD070 and its niacin derivative WK1 (concentration: 40 µM; for 48 h) as determined by flow cytometry and compared to the DMSO treated control cells. The treatments and Annexin V staining were performed in triplicate and the medians ± standard deviations are depicted. ( d ) Percentage of cleaved caspase 3 positive BL2 (as Burkitt model) and SuDHL4 (as GCB-DLBCL model) cells treated with 40 µM of AMD070 or 20 µM and 40 µM of its niacin derivative WK1 for 24 h as determined by flow cytometry and compared to the DMSO treated control cells. The treatments and cleaved caspase staining were performed in triplicate and the medians ± standard deviations are depicted.

Article Snippet: First, either the CXCR4 antagonists AMD3100, AMD070 or WK1 to a final concentration between 0.01–20 µM or blocking antibodies (10 µg/mL) targeting CXCR4 (clone: 9C4, MBL, Woburn, MA, USA), CXCR7 (clone: 11G8, ChemoCentryx Inc., Mountain View, CA, USA), or isotype controls were added to the cells and incubated for 45 min at 37 °C.

Techniques: Inhibition, Proliferation Assay, Concentration Assay, Flow Cytometry, Staining